ON
ONCO.NLB
—
—
Biotechnology & Medical Research
Onco-Innovations Ltd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,98
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Onco-Innovations Ltd develops and commercializes diagnostic tools for oncology, generating revenue through product sales and research partnerships.
Business. Onco-Innovations Ltd (ONCO.NLB) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is listed under the ticker ONCO.NLB. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ONCO.NLB. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Onco-Innovations Ltd (ONCO.NLB) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is listed under the ticker ONCO.NLB. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
AI synthesis
GENERATEDOnco-Innovations has a fully diluted share count of 59,565,858 shares, with no difference between basic and diluted shares, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided for comparison. Without revenue, EBITDA, or net income data, it is not possible to assess Onco-Innovations' returns relative to industry benchmarks.
The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment breakdown is provided, and there is no information on the geographic distribution of its sales or operations.
Growth trajectory data is incomplete. No revenue history or outlook figures are available to determine the company's growth rate or future expectations.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data. No dilution risk is currently flagged, but the absence of financial disclosures limits the ability to evaluate capital structure stability.
Recent events, such as filings or transcripts, are not available in the source documents provided. No material developments or disclosures have been identified to date.
Key takeaways
- Onco-Innovations operates in the Biotechnology & Medical Research industry, focusing on healthcare diagnostics.
- The company has no dilution risk based on current share counts, but liquidity risk cannot be assessed.
- No profitability or growth metrics are available for comparison with industry benchmarks.
- Revenue concentration and geographic exposure are not disclosed, limiting visibility into operational risk.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$1,00
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Corporate eventM&A horizon
M&A probabilityconf 5 %
Probability
5 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-23 · 1,8× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-07-27
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
M&A probabilityconf —
Probability
5 %
Base rate
3 %
Band
Moderate
180-day horizon · target 2027-01-23 · 1,8× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 241 514 sh1 transactions1 insiders
- 10% owner · Make-whole right (right to acquire) → Common StockDisposed 241 514other · 2025-07-14
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Source documents
- Onco-Innovations Ltd Market data — financials · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
Net buying3 buys · 3 sellsnet $8K5 insiders · last 365d
- 10% owner · Class A SharesSold 49 710 @ $0,69$34K · 2026-04-21
- 10% owner · Class A SharesSold 94 462 @ $0,75$71K · 2026-04-20
- 10% owner · Class A SharesBought 34 636 @ $0,73$25K · 2026-04-17
- 10% owner · Class A SharesSold 53 867 @ $0,73$39K · 2026-04-16
- 10% owner · Class A SharesBought 92 554 @ $0,76$70K · 2026-04-15
- 10% owner · Class A SharesBought 74 350 @ $0,77$57K · 2026-04-14
- Director · Common StockOther 618 · 2025-08-15
- Director · Common StockOther 618 · 2025-08-15
- Director · Common StockOther 39 · 2025-08-15
- Director · Common StockOther 20 · 2025-08-15
- Director · Common StockOther 39 · 2025-08-15
- Director · Common StockOther 39 · 2025-08-15
- Director · Common StockOther 618 · 2025-08-15
- Director · Common StockOther 618 · 2025-08-15
Short positioning
122.2Kshares short+98.4% vs prior
1days to cover
28.3%short of daily vol
8.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ONCO.NLBCanonical
— · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Evidence & claims
From filings & derived data- Net margin (FY 2025-12-31): -1,721.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 99.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 68.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 76.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 7.8%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -40.0%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -87.6%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -50.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -11.5%Derived (calculated)
- Gross margin (FY 2025-12-31): 77.6%Derived (calculated)
- Return on equity (FY 2025-12-31): -89.0%Derived (calculated)
- Return on assets (FY 2025-12-31): -56.3%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.66xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.58xDerived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -67.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 84.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 99.1%Derived (calculated)
- Current assets (annual): USD 6.07MSEC XBRL filing
- Total liabilities (annual): USD 9.16MSEC XBRL filing
- Pre-tax income (annual): USD -14.03MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -17SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -17SEC XBRL filing
- Total operating expenses (annual): USD 18.49MSEC XBRL filing
- Gross profit (annual): USD 632.91KSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-08 21:47 UTCEVENTHa Price Listing ONCO price below 1 ($0.9324) — US continued-listing minimum-bid threshold
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-28 03:14 UTCHOLDERInstitutional holding changed
2026-06-28 03:14 UTCHOLDER1 institutional position change flagged
2026-04-21 00:00 UTCINSIDER6 insider transactions — 2026-04 · $297k gross
2026-04-21INSIDERHRT FINANCIAL LP sold 49.7k sh Class A Shares — 10% owner ~$34k
2026-04-20INSIDERHRT FINANCIAL LP sold 94.5k sh Class A Shares — 10% owner ~$71k
2026-04-17INSIDERHRT FINANCIAL LP bought 34.6k sh Class A Shares — 10% owner ~$25k
2026-04-16INSIDERHRT FINANCIAL LP sold 53.9k sh Class A Shares — 10% owner ~$39k
2026-04-15INSIDERHRT FINANCIAL LP bought 92.6k sh Class A Shares — 10% owner ~$70k
2026-04-14INSIDERHRT FINANCIAL LP bought 74.3k sh Class A Shares — 10% owner ~$57k
2025-08-15 00:00 UTCINSIDER8 insider transactions — 2025-08
2025-08-15INSIDERMeier Thomas transacted 618 sh — Director
2025-08-15INSIDEROakley Andrew John transacted 618 sh — Director
2025-08-15INSIDERTarsh Simon transacted 39 sh — Director
2025-08-15INSIDEROakley Andrew John transacted 20 sh — Director
2025-08-15INSIDERMeier Thomas transacted 39 sh — Director
2025-08-15INSIDERRamdeen Timothy R. transacted 39 sh — Director
2025-08-15INSIDERTarsh Simon transacted 618 sh — Director
2025-08-15INSIDERRamdeen Timothy R. transacted 618 sh — Director
2025-07-14 00:00 UTCINSIDER2 insider transactions — 2025-07 1 derivative
2025-07-14INSIDERAltos Venture AG disposed of 241.5k sh Make-whole right (right to acquire) — 10% owner
2025-03-23 00:00 UTCINSIDER1 insider transaction — 2025-03
2024-12-20 00:00 UTCINSIDER2 insider transactions — 2024-12
2024-09-26 00:00 UTCINSIDER7 insider transactions — 2024-09
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage